Federal Marijuana Rescheduling Faces Unexpected Hurdle at DEA

Efforts to reclassify marijuana at the federal level have hit a significant obstacle, as the Drug Enforcement Administration (DEA) appears hesitant to proceed with the proposed changes. Despite the U.S. Department of Health and Human Services (HHS) recommending last year that cannabis be moved from Schedule I to Schedule III—acknowledging its medical value and lower potential for abuse—the DEA has yet to act.

The review, initiated under President Joe Biden’s directive, was seen as a major turning point in national cannabis policy. The move to Schedule III would not legalize marijuana but could ease research restrictions and allow cannabis companies to claim tax deductions currently prohibited under Schedule I classification.

However, according to a recent report, DEA officials remain cautious, and internal resistance is reportedly slowing progress. Critics argue that the agency’s delay undermines public trust and contradicts the Biden administration’s stated commitment to reform.

While the Department of Justice has not provided a clear timeline, advocates and lawmakers continue to call for swift action, citing both scientific consensus and widespread public support for change. Until the DEA finalizes its review, federal cannabis policy remains in limbo—leaving patients, businesses, and regulators in a prolonged state of uncertainty.

Dabbin-Dad Newsroom